Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written feedback from the U.S. Food and Drug Administration ("FDA") and central Institutional Review Board ("IRB") approval, with modifications, for its optimized Phase 2 clinical study of Teverelix® in men following a first episode of acute urinary retention ("AUR").

The randomized, double-blind, placebo-controlled, multicenter study, designated ANT-2111-02, is a novel study designed to evaluate the pharmacodynamic effects of Teverelix DP, a long-acting gonadotropin-releasing hormone ("GnRH") antagonist, on prostate volume and urinary function in men following a first episode of AUR.